Radiopharmaceuticals are medications that contain radioactive (isotopes), which are used for the treatment or diagnose of cancer. These medications can be administered into patient’s body orally, intravenously or interstitially (inserted into a cavity in the body). Radiopharmaceuticals are inserted into the body and when it reaches the targeted area of the body, it releases radioactive agents to destroy the tumor cells. Fludeoxyglucose F 18, Gallium Citrate Ga 67, Indium In 111 Pentetreotide, Methionine C 11, Radioiodinated Iobenguane, Sodium Fluoride F 18, Technetium Tc 99m Arcitumomab, Technetium Tc 99m Nofetumomab Merpentan are the oral radiopharmaceuticals used in the diagnosis of cancer
Radiopharmaceuticals can be used to treat following cancers:
- Thyroid cancer
- Brain cancer
- Lymphoma
- Cancers that have spread to the bones
Market Dynamics
Increasing number of drug approvals from regulatory bodies is expected to drive the growth of the global oncology radiopharmaceutical market during the forecast period. For instance, in May 2020, PETNET Solutions, Inc., a Siemens Healthineers company, and Zionexa USA, a wholly-owned subsidiary of Zionexa SAS, announced that the U.S. Food and Drug Administration (FDA) approved Cerianna (fluoroestradiol F 18) injection for intravenous use. Cerianna (fluoroestradiol F 18) is the first FDA-approved F-18 PET imaging agent specifically indicated for use in patients with recurrent or metastatic breast cancer.
Increasing number of inorganic growth strategies by market players is expected to drive the growth of global oncology radiopharmaceuticals market. For instance, in June 2021, Bayer AG a pharmaceuticals and life science company announced that the company signed an agreement to acquire Noria Therapeutics Inc. and PSMA Therapeutics Inc. Noria Therapeutics Inc is a radiotherapy company developing targeted therapeutic and imaging radiopharmaceuticals. This acquisition will provide rights to Bayer to differentiate alpha radionuclide therapy based on actinium-225 and a small molecule targeting prostate-specific membrane antigen (PSMA).
Key features of the study:
- This report provides an in-depth analysis of the global oncology radiopharmaceutical market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global oncology radiopharmaceutical market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
- Key companies covered as a part of this study include Siemens Healthcare GmbH, Novartis AG, Curium, GE Healthcare, Lantheus Medical Imaging, Inc., International Isotopes, Inc., Nordion, Eckert & Zieger, Acrotech Biopharma, Blue Earth Diagnostics, Zionexa, Bayer AG, Jubilant Pharma Limited, and Cardinal Health
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global oncology radiopharmaceutical market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global oncology radiopharmaceutical market
Detailed Segmentation:
- Global Oncology Radiopharmaceutical Market, By Type:
- Radium-223 dichloride
- Sodium iodide I-131
- Lobenguane iodine-131
- Lutetium-177
- Yttrium-90
- Fludeoxyglucose F 18
- Gallium Citrate Ga 67
- Technetium-99m
- Others
- Global Oncology Radiopharmaceutical Market, By Route of Administration:
- Global Oncology Radiopharmaceutical Market, By Application:
- Global Oncology Radiopharmaceutical Market, By End User:
- Diagnostic Centers
- Hospitals and Clinics
- Cancer Research Institutes
- Global Oncology Radiopharmaceutical Market, By Region:
- North America
- By Type:
- Radium-223 dichloride
- Sodium iodide I-131
- Lobenguane iodine-131
- Lutetium-177
- Yttrium-90
- Fludeoxyglucose F 18
- Gallium Citrate Ga 67
- Technetium-99m
- Others
- By Route of Administration:
- By Application:
- By End User:
- Diagnostic Centers
- Hospitals and Clinics
- Cancer Research Institute
- By Country:
- Latin America
- By Type:
- Radium-223 dichloride
- Sodium iodide I-131
- Lobenguane iodine-131
- Lutetium-177
- Yttrium-90
- Fludeoxyglucose F 18
- Gallium Citrate Ga 67
- Technetium-99m
- Others
- By Route of Administration:
- By Application:
- By End User:
- Diagnostic Centers
- Hospitals and Clinics
- Cancer Research Institute
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Type:
- Radium-223 dichloride
- Sodium iodide I-131
- Lobenguane iodine-131
- Lutetium-177
- Yttrium-90
- Fludeoxyglucose F 18
- Gallium Citrate Ga 67
- Technetium-99m
- Others
- By Route of Administration:
- By Application:
- By End User:
- Diagnostic Centers
- Hospitals and Clinics
- Cancer Research Institute
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Type:
- Radium-223 dichloride
- Sodium iodide I-131
- Lobenguane iodine-131
- Lutetium-177
- Yttrium-90
- Fludeoxyglucose F 18
- Gallium Citrate Ga 67
- Technetium-99m
- Others
- By Route of Administration:
- By Application:
- By End User:
- Diagnostic Centers
- Hospitals and Clinics
- Cancer Research Institute
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
- By Type:
- Radium-223 dichloride
- Sodium iodide I-131
- Lobenguane iodine-131
- Lutetium-177
- Yttrium-90
- Fludeoxyglucose F 18
- Gallium Citrate Ga 67
- Technetium-99m
- Others
- By Route of Administration:
- By Application:
- By End User:
- Diagnostic Centers
- Hospitals and Clinics
- Cancer Research Institute
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Type:
- Radium-223 dichloride
- Sodium iodide I-131
- Lobenguane iodine-131
- Lutetium-177
- Yttrium-90
- Fludeoxyglucose F 18
- Gallium Citrate Ga 67
- Technetium-99m
- Others
- By Route of Administration:
- By Application:
- By End User:
- Diagnostic Centers
- Hospitals and Clinics
- Cancer Research Institute
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Siemens Healthcare GmbH *
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Novartis AG
- Curium
- GE Healthcare
- Lantheus Medical Imaging, Inc.
- International Isotopes, Inc.
- Nordion
- Eckert & Zieger
- Acrotech Biopharma
- Blue Earth Diagnostics
- Zionexa
- Bayer AG
- Jubilant Pharma Limited
- Cardinal Health
“*” marked represents similar segmentation in other categories in the respective section.
